Improved kidney graft survival in Eurotransplant by HLA-DR matching and prospectively given blood transfusions. by Persijn, G. G. et al.
IMPROVED KIDNEY GRAFT SURVIVAL IN
EUROTRANSPLANT BY HLA-DR MATCHING AND
PROSPECTIVELY GIVEN BLOOD TRANSFUSIONS
G. G. PERSIJN,* A. VAN LEEUWEN,*-* J. PARLEVLIET,**
B. COHEN,* Q. LANSBERGEN,* * J. D'AMARO** and J. J. VAN ROOD*
*Eurotransplant Foundation, University Hospital, 2333 AA Leiden, The Netherlands
*'Department of immunohaematology, University Hospital, 233 AA Leiden, The Netherlands
This work was in part supported by the Dutch Organisation for Health Research
(TNO), the Dutch Fountation for Medical Research (FUNGO), which is sub-
sidized by the Dutch Foundation for the Advancement of Pure Research (ZWO),
the J. A. Cohen Institute for Radiopathology and Radiation Protection (IRS)
and the Dutch Kidney Foundation.
CADAVERIC kidney graft survival is influenced by many different factors. Two
such factors are matching for the HLA-DR determinants between donor and
recipient and blood transfusion(s) given to the recipient before transplantation.
Indeed, recent reports have shown that matching for the HLA-DR determinants
and the effect of pre-transplant blood transfusions play an important role in
predicting kidney graft outcome in human cadaveric renal transplantation 1, 2, 3,
4, 5. Most of these retrospective studies were critisized because of selection
criteria, insufficient accuracy, heterogeneity, patient management etc. To tackle
the problem of retrospective studies as many patients as possible on the Euro-
transplant waiting list were typed prospectively for the HLA-DR determinants.
Kidney donors were typed before or at time of transplantation and are therefore
considered as prospective.
Concerning the blood transfusion effect on kidney graft survival a prospective
blood transfusion protocol was started in 1977 in the Netherlands. Non-transfused
kidney patients waiting for a cadaveric kidney transplant received either one
unit of washed ABO identical blood (i.e. leucocyte poor blood) or one or three
units of cotton wool filtered blood (i.e. leucocyte free blood). Due to the bad
kidney graft survival obtained in non-transfused kidney patients a prospective
non-transfused control group is lacking 6.
We present here the results of the effect of matching for the HLA-DR deter-
minants in 599 kidney transplants and the effect of prospectively given blood
transfusions in 52 patients.
PATIENTS, MATERIALS AND METHODS
HLA-DR analysis
A total of 599 cadaveric kidney transplants done under the auspices of
Eurotransplant were studied. Of them 72 were second transplants and six were
54third transplants. All but 25 patients had had blood transfusions before trans-
plantation. Immunosuppressive therapy mostly consisted of azathiopyrine and
prednisone. In some transplantation centres, anti-thymocyte globulin was used
as part of pilot studies. Graft survival was considered successful if the recipient
could live without haemodialysis. Non-immunological and technical failures were
not excluded from the analysis.
All HLA-A and -B typings of the kidney patients were performed twice, once
in the regional typing center and once in the Eurotransplant Reference Center
in Leiden, both with the Eurotransplant serum set which recognized all official
HLA and Workshop -A and -B specificities. All donors and recipients were typed
with anti-sera recognizing the HLA-DR 1-8 specificities, according to the defini-
tions used during the Seventh International Histocompatibility Workshop in
Oxford. Typing was performed before or at time of transplantation in 488 cases
and is therefore considered as prospective. No specific B-cell cross-matching was
done. The two-colour fluorescence serological method was used for HLA-DR typ-
ing and about half of all typings were performed twice 7. All patients' sera were
screened at least once every two months for the presence of lymphocytotoxic
antibodies against a panel of 50 selected HLA-typed donors. In this panel, all
known HLA-A and -B antigens are represented. Cross-matching by the standard
microlymphocytotoxic test was performed with the most recent serum sample of
the recipient available in the donor tissue typing laboratories. Eventually, the
cross-match was repeated in the transplantation center with the serum samples
containing leucocyte antibody activity. A negative result was mandatory for
transplantation of the recipient.
Graft survival times were estimated using the actuarial life table method x.
The chi square test was used to determine the significance of the differences in
the observed numbers of successes and failures in each class.
Blood transfusion study
In March 1977, the decision was taken in the Netherlands to stop transplanting
non-transfused kidney patients waiting for a cadaveric kidney transplant. A
blood transfusion protocol was introduced with two arms. One arm consisted of
a group of never-transfused and/or nulli-parous patients who received 1 unit of
twice-washed ABO identical blood (i.e. leucocyte poor blood). The amount of
leucocytes in the blood was decreased by washing to 40-60 per cent. The choice
of washed erythrocytes was based on the fact that this blood product had usually
been given in our retrospective study and the risk of immunization against HLA
antigens was low, especially when only one transfusion was given 6.
The other arm of the protocol included patients that were given I or 3 units
of cotton-wool filtered blood. This is a technique originally described by Diepen-
horst et al. which makes the blood almost completely leucocyte free 9. Blood for
the transfusions was obtained from normal healthy Dutch Red Cross volunteers,
who are checked at least once annually and screened by the RIA method for
the presence of Hbs Ag - antigens to avoid the transmission of hepatitis B. As
a rule, the blood was less than 3 days old.
55Washed erythrocytes (leucocyte poor blood)
Thirty-one male and nine female patients were transfused with 1 unit of
washed (i.e. leucocyte poor) erythrocytes. Their age ranged from 16 to 56 years
(mean: 36 years). The haemodialysis period varied from 3 to 68 months with a
mean of 19 months. All patients who were transfused according to this protocol
but who later required additional transfusions prior to transplantation for medical
reasons were excluded from this study. The interval between blood transfusion
and transplantation varied from 21 days to 1108 days (mean: 251 days). Most of
the serum samples tested after the transfusion(s) of these patients showed no
detectable lymphocytotoxic antibody activity. In two cases, very weak activity
amounting to approximately 5 per cent kill above background developed against
part of the panel but this activity disappeared when subsequent serum samples
were screened. The follow-up time in this study was at least one month. All
patients received one to six transfusions, mostly of leucocyte free blood, during
transplantation.
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Figure I
Kidne) graft survival and HLA-DR matching. Note that 13 patients received an
HLA A, B and DR identical kidney. Kidney graft survival in his group is 92 per
cent after 2 years, while the group with no mismatches for HLA-DR has 80 per
cent after 2 years. The numbers between brackets are the total number of patients
each group (p = 0.003).
56Filtered blood (leucocyte free blood)
Six male patients received I unit of cotton-wool filtered, i.e. leucocyte free,
blood. Their mean age was 36.5 years (range: 31-56 years). Three male and three
female patients received 3 units of cotton-wool filtered blood. In this group, the
mean age was 37.5 years (range: 16-50). The 1 and 3 unit group of patients
are combined for analysis because of the small number of patients. The hemo-
dialysis period varied from 3-21 months with a mean of 10 months. with a mean
of 10 months. In the one unit group, the interval between transfusion and
transplantation varied from 35 to 179 days (mean: 120 days). In the group given
3 units, this interval varied from 17 to 371 days (mean: 127 days) after the last
transfusion. Here too, all patients received transfusions of leucocyte free blood,
varying from 1 to 4 units, during the operation.
RESULTS
HLA-DR analysis
Figure 1 shows the results in 599, mostly prospectively HLA-DR typed donor/
recipient combinations. Kidney graft survival was 80 per cent after 2 years in
the group with no HLA-DR mismatches. This is significantly different from
EFFECT OF HLA.DR MATCHING
IN NON -TRANSFUSED PATIENTS
% GRAFT
SURVIVAL
100
90
80
70
60
50
40
30
(N 25)
NR OF MISM
O (Nz5)
1 (N:1O)
2 (N:10)
1 2 3 4 5 6
Figure 2
The effect of HLA-DR matching in 25 non-transfused patients. Five patients who
received an HLA-DR identical kidney have 80 per cent graft survival after 6
months.
57graft survival in the groups with one or two HLA-DR mismatches (p = 0.003).
Thirteen donor/recipient pairs which had no mismatches for the HLA-DR
antigens did not have mismatches for the HLA-A and -B antigens as well. Graft
survival in this particular group was 92 per cent after two years. The group of
recipients which had one HLA-DR mismatch with their donor had a graft
survival of 60 per cent after two years. This value is the same as the results in
the group with two HLA-DR mismatches.
The influence of HLA-DR matching in 25 patients who never had been trans-
fused or who had received only leucocyte free blood is shown in figure 2. Graft
survival in five patients who had no HLA-DR mismatches with their donor was
80 per cent after six months. In the non-transfused patients who had two HLA-
DR mismatches with their donor, 30 per cent graft survival was obtained after
six months. The group with one HLA-DR mismatch showed intermediate values
namely 60 per cent after six months. These small numbers of patients do not
permit us to draw any statistical conclusions from these results.
Blood transfusion analysis
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Figure 3
The effect of prospective blood transfusions on kidney graft survival. The
numnbers indicate the patients at risk. Graft survival is 80 per cent after 200 days
in the group who received one leucocyte poor blood transfusion. Patients who
received I or 3 units of leucocvte free have 33 per cent graft survival after 200
days.
58Figure 3 shows that kidney graft survival in patients prospectively transfused
with one unit of washed erythrocytes is 80 per cent after 200 days. Eight recipients
had a graft failure. In four cases, this was due to non-immunological causes such
as myocardical infarction and pneumonia. Four patients lost their kidney due to
rejection.
Figure 3 also shows the surprising finding that kidney graft survival was very
poor in patients given 1 or 3 unit(s) of leucocyte free blood i.e. 33 per cent after
200 days. Eight patients lost their graft due to irreversible rejection. This is
significantly different from the survival in the group prospectively given one
tranfusion of leucocyte poor blood (,x' 6.41, p = 0.01).
DISCUSSION
Our data show that good graft survival is obtained in unrelated donor/recipient
combinations with no HLA-DR mismatches. Kidney graft survival was worse in
the group who had one or two HLA-DR mismatches, but surprisingly the latter
did much better than in the retrospective study.
The difference in kidney graft survival between the group with one HLA-DR
and the group with two HLA-DR mismatches in that study was remarkable 1. In
the data presented here, this difference is not observed. We have no explanation
for those different findings. Perhaps we are seeing the results of improved patient
management and monitoring regarding immunosuppressive therapy 10.
The excellent graft survival in patients who receive an HLA-A, -B and -DR
identical kidney is remarkable. The role of the interaction between HLA-A and
-B and HLA-DR on graft survival is not yet fully understood and remains a
subject for further study. We think that, especially in patients who have
developed leucocyte antibodies, HLA-A and -B matching is of overriding impor-
tance and has the first priority.
The results of this study demonstrate that HLA-DR typing and matching in
the cadaveric donor selection is very feasible. More than 20 per cent of the
recipients received an organ with no HLA-DR mismatches. That proportion is
much higher than ever obtained in matching for HLA-A and -B antigens alone.
However one has to be careful, since typing for the HLA-DR determinants is
often a very difficult procedure especially with potential kidney donors. Therefore,
regular quality controls and workshops regarding HLA-DR typing should be
held. Special attention should be given to the different techniques and variety of
donor material like spleen, lymphnode etc.
Concerning pretransplant blood transfusions, this prospective study clearly
shows that a single unit of leucocyte poor blood given prior to transplantation
can lead to prolonged cadaveric kidney graft survival. Data obtained in this
study are reliable because they have been obtained prospectively and, without
exception, they originate from dialysis centers in the Netherlands which can be
considered as a homogenous group. Opelz et al. did not find a similar beneficial
effect of one transfusion in corresponding groups of recipients but his study was
retrospective and encompasses a heterogenous patient population from many
59different centers ". Other authors have shown an improvement in kidney graft
survival in patients who had received very few and even one blood transfusion
prior to transplantation 12 13, 14, 15 Since most of these reports refer to retro-
spective analysis it is obvious that these patients received blood transfusions due
to a variety of indications and the posibility of a potentially important variable
has not entirely been excluded. They received at least one transfusion prior to
transplantation.
A new and unexpected finding in ouI study was that 8 out of 12 patients who
received 1 or 3 unit(s) of leucocyte free blood rejected their transplanted kidney
within 120 days. This extreme divergence from the excellent survival in the
group given one transfusion of leucocyte poor blood cannot be explained by the
quality of the HLA matching, because the average HLA mismatch between
donor and recipient was the same for all groups, namely 1.5. The poor results
obtained in the leucocyte free group are comparable to the group of patients
which received no transfusions at all.
The favourable kidney outcome in patients "pretreated" with only one unit of
washed erythrocytes (leucocyte poor) has many important implications for non-
transfused hemodialysis patients awaiting a cadaveric kidney graft. The risk of
immunization against HLA antigens of the kidney donor is minimized by the use
of leucocyte poor blood. Another advantage of our policy of transfusing only
one unit of leucocyte poor blood prior to transplantation is that the risk of
transmitting infectious diseases such as hepatitis B and cytomegaly is reduced.
So far, we have not had a single case of such a disease after transfusion.
The mechanism underlying the beneficial effect of blood transfusion in kidney
allograft survival is unclear. It seems unlikely that kidney graft survival is
increased by specific enhancing antibodies such as anti-HLA-DR antibodies in
patients who have received only one transfusion. We do not exclude the possibi-
lity that the improved graft survival of pretransfused patients is due to the
triggering of a non-specific suppressor mechanism by leucocyte poor blood trans-
fusions. That hypothesis is already under investigation with special attention to
these prospectively transfused patients .16
Finally, the interaction between blood transfusions and HLA-DR matching is
an interesting phenomenon. The effect of pretransplant blood transfusions might
be more outspoken in the group of patients who receive a cadaveric graft with
two HLA-DR mismatches. Good graft survival was obtained in non-transfused
patients or in patients who had received only leucocyte free blood only when they
received a kidney with no HLA-DR mismatches. On the contrary, graft survival
was far worse in the group with two HLA-DR mismatches. This observation
confirms the finding of the Oxford group 17. Furthermore, our group noticed, as
did others, that graft survival improvement due to matching for one HLA-DR
determinant alone appears also to depend on previous blood transfusions. This
phenomenon is well known as kidney graft survival in parent-child combinations
is much better when the recipient had received blood transfusions prior to trans-
plantation. These combinations share, as a rule, only one HLA-DR deter-
minant 18.
60Concluding we suggest that blood transfusions probably have an additive or
synergistic effect on the influence of HLA-DR matching in renal transplantation.
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